Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome

Am J Ophthalmol. 1992 Mar 15;113(3):331-3. doi: 10.1016/s0002-9394(14)71588-0.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Administration, Oral
  • Adolescent
  • Antiprotozoal Agents / administration & dosage
  • Antiprotozoal Agents / therapeutic use*
  • Atovaquone
  • Eye Infections, Parasitic / complications
  • Eye Infections, Parasitic / drug therapy
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Male
  • Naphthoquinones / administration & dosage
  • Naphthoquinones / therapeutic use*
  • Toxoplasmosis, Ocular / complications
  • Toxoplasmosis, Ocular / drug therapy*

Substances

  • Antiprotozoal Agents
  • Naphthoquinones
  • Atovaquone